Sensus Healthcare (NASDAQ:SRTS) Price Target Raised to $14.00

Sensus Healthcare (NASDAQ:SRTS) had its price objective lifted by Maxim Group from $12.00 to $14.00 in a research report sent to investors on Friday morning, MarketBeat reports. Maxim Group currently has a buy rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Sensus Healthcare in a research report on Monday, August 12th.

Sensus Healthcare Trading Up 4.8 %

Shares of Sensus Healthcare stock opened at $7.64 on Friday. Sensus Healthcare has a twelve month low of $2.02 and a twelve month high of $8.29. The firm has a market capitalization of $125.22 million, a PE ratio of 13.40 and a beta of 1.04. The firm’s 50-day moving average price is $6.37 and its 200 day moving average price is $5.95.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC raised its holdings in Sensus Healthcare by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after acquiring an additional 11,525 shares during the last quarter. XTX Topco Ltd increased its holdings in shares of Sensus Healthcare by 76.0% in the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after purchasing an additional 13,619 shares during the last quarter. Truvestments Capital LLC acquired a new stake in shares of Sensus Healthcare in the third quarter valued at approximately $32,000. Cubist Systematic Strategies LLC purchased a new position in Sensus Healthcare during the second quarter worth approximately $156,000. Finally, Marshall Wace LLP boosted its stake in Sensus Healthcare by 152.4% during the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after buying an additional 46,732 shares during the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.